TrialNature communications2022

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

Hongwei Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.